Capital Planning Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Planning Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,159	Closed	-$329K	–	138
2022 Q1	$329K	Sell	7,159 -196,617	-96%	-$9.37M	0.07%	122
2021 Q4	$12.5M	Sell	203,776 -14,896	-7%	-$1.03M	2.38%	9
2021 Q3	$16.3M	Buy	218,672 +3,225	+1%	+$271K	3.39%	6
2021 Q2	$19.9M	Buy	215,447 +11,150	+5%	+$948K	4.09%	4
2021 Q1	$18.1M	Buy	204,297 +23,587	+13%	+$2.34M	4.06%	4
2020 Q4	$16.9M	Buy	180,710 +9,669	+6%	+$770K	4.14%	4
2020 Q3	$10.9M	Buy	171,041 +9,445	+6%	+$553K	2.99%	8
2020 Q2	$8.43M	Buy	161,596 +17,207	+12%	+$738K	2.51%	10
2020 Q1	$4.52M	Buy	+144,389	New	+$4.82M	1.69%	17

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Capital Planning Advisors's ARKG Position: Q2 2022 in Review

Capital Planning Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 7,159 shares — an estimated $329K sold.

Capital Planning Advisors first reported a position in ARKG in Q1 2020 and held it in 9 quarters. The position peaked at $19.9M in Q2 2021. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

Capital Planning Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
Capital Planning Advisors sold 7,159 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $329K.
Capital Planning Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2020 and held it in 9 quarters.
Capital Planning Advisors's ARK Genomic Revolution ETF position peaked at $19.9M in Q2 2021.
334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Capital Planning Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.